New update out.......... CytoDyn Sponsored Rese
Post# of 154134
(Total Views: 271)
Posted On: 08/02/2019 6:05:51 AM
New update out..........
CytoDyn Sponsored Research Reaffirms the Role of CCR5 in Cancer Biology and Provides a New Potential Cancer Treatment Modality
Exciting results from Daniel Lindner, M.D., Ph.D. at the Cleveland Clinic with leronlimab on human colon carcinoma
VANCOUVER, Washington, Aug. 02, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the successful completion of a series of pre-clinical studies by Dr. Daniel Lindner, M.D., Ph.D. at the Cleveland Clinic with leronlimab (PRO140) on human colon carcinoma in humanized mouse models.
The ability of leronlimab to inhibit colon carcinoma was investigated in mice with a human immune system. The data indicate that rapid tumor growth is associated with high CCR5 expression and that leronlimab can suppress colon carcinoma growth in both low and high CCR5 expression tumors. The results also define a potential role for the human immune system in tumor control. These results together provide the basis for the potential use of leronlimab as a new therapeutic modality for human solid tumors expressing CCR5.
"The results that we are announcing today provide a potential, significant opportunity in oncology,” stated CytoDyn President and CEO, Nader Pourhassan, Ph.D. "We are encouraged by the pipeline of opportunities leronlimab continues to create, with potentially accelerated path to approval in several cancer indications given the high unmet medical need and leronlimab's proven safety record in over 800 patients dosed to date across several therapeutic indications with no drug-related serious adverse advents. A tremendous thanks to Dr. Lindner at the Cleveland Clinic for his design and oversight of these key pre-clinical studies," Dr. Pourhassan concluded.
"I am honored to have had the opportunity to investigate the role of leronlimab in cancer biology,” stated Daniel Lindner, M.D., Ph.D. at the Cleveland Clinic. "Our research provides ground-breaking insight into basic cancer biology, immune involvement in cancer suppression and has identified a potential new therapeutic modality to influence cancer patients' survival."
CytoDyn Sponsored Research Reaffirms the Role of CCR5 in Cancer Biology and Provides a New Potential Cancer Treatment Modality
Exciting results from Daniel Lindner, M.D., Ph.D. at the Cleveland Clinic with leronlimab on human colon carcinoma
VANCOUVER, Washington, Aug. 02, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the successful completion of a series of pre-clinical studies by Dr. Daniel Lindner, M.D., Ph.D. at the Cleveland Clinic with leronlimab (PRO140) on human colon carcinoma in humanized mouse models.
The ability of leronlimab to inhibit colon carcinoma was investigated in mice with a human immune system. The data indicate that rapid tumor growth is associated with high CCR5 expression and that leronlimab can suppress colon carcinoma growth in both low and high CCR5 expression tumors. The results also define a potential role for the human immune system in tumor control. These results together provide the basis for the potential use of leronlimab as a new therapeutic modality for human solid tumors expressing CCR5.
"The results that we are announcing today provide a potential, significant opportunity in oncology,” stated CytoDyn President and CEO, Nader Pourhassan, Ph.D. "We are encouraged by the pipeline of opportunities leronlimab continues to create, with potentially accelerated path to approval in several cancer indications given the high unmet medical need and leronlimab's proven safety record in over 800 patients dosed to date across several therapeutic indications with no drug-related serious adverse advents. A tremendous thanks to Dr. Lindner at the Cleveland Clinic for his design and oversight of these key pre-clinical studies," Dr. Pourhassan concluded.
"I am honored to have had the opportunity to investigate the role of leronlimab in cancer biology,” stated Daniel Lindner, M.D., Ph.D. at the Cleveland Clinic. "Our research provides ground-breaking insight into basic cancer biology, immune involvement in cancer suppression and has identified a potential new therapeutic modality to influence cancer patients' survival."
(1)
(0)